1. DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature.
- Author
-
Kelly, Christina, Raymond, Caitlin, Han, Song, Lin, Youmin, Chen, Linyijia, Huang, Gengming, and Dong, Jianli
- Subjects
THERAPEUTIC use of antineoplastic agents ,ADENOCARCINOMA ,CANCER invasiveness ,COMPUTED tomography ,PROTEIN-tyrosine kinase inhibitors ,MAGNETIC resonance imaging ,TUMOR markers ,CHROMOSOME abnormalities ,METASTASIS ,GENE expression profiling ,MICROARRAY technology ,LUNG cancer ,GENETIC mutation ,DIAGNOSIS of brain abnormalities ,BACKACHE ,EPIDERMAL growth factor receptors - Abstract
Non–small cell lung cancer (NSCLC) has been found to have recurrent genetic abnormalities, and novel therapies targeting these aberrations have improved patient survival. In this study, specimens from benign tissue, primary tumors, and brain metastases were obtained at autopsy from a 55-year-old White female patient diagnosed with NSCLC and were examined using next-generation sequencing (NGS) and chromosomal microarray assay (CMA). No genetic aberrations were noted in the benign tissue; however, NGS identified a mutation in the KRAS proto-oncogene, GTPase (KRAS): KRAS exon 2 p.G12D in primary and metastatic tumor specimens. We observed 7 DNA copy number aberrations (CNAs) in primary and metastatic tumor specimens; an additional 7 CNAs were exclusively detected in the metastatic tumor specimens. These DNA alterations may be genetic drivers in the pathogenesis of the tumor specimen from our patient and may serve as biomarkers for the classification and prognosis of NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF